Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in Watford, the United Kingdom.

Earnings data Q4 2019

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

Smith & Nephew shares are down 3.6% since February, but management has increased top-line growth guidance for fiscal 2022. The Orthopedics business unit is showing strong growth potential, with momentum in the EVOS franchise and expansion opportunities for REGENETEN in Sports Medicine. Technical analysis suggests a potential double-bottom reversal pattern, with shares potentially reaching $30+ and even returning to 2021 highs of over $40 if investors can remain patient.

Smith & Nephew: Orthopedics Growth Continues To Drive Sales Forward

Smith & Nephew (SNN) will pay an initial cash consideration of $180 million at closure, with an additional $150 million based on financial performance to acquire CartiHeal.

Smith & Nephew (SNN) New Buyout Expands Sports Medicine Suite

Smith & Nephew PLC (LSE:SN) has announced the acquisition of knee cartilage regeneration technology developer CartiHeal. Under the agreement, the FTSE 100-listed medical equipment manufacturer will pay US$180 million for CartiHeal and up to a further US$170 million based on financial performance.

Smith & Nephew acquires cartilage regeneration firm

Smith & Nephew PLC (LSE:SN)'s underperformance is set to change, according to Goldman Sachs (NYSE:GS). The investment bank has initiated coverage of the medical technology outfit with a buy rating and price target of 1,400p, around 40% higher than today's share price.

Smith & Nephew's underperformance set to change, says Goldman

Amcor Plc

AstraZeneca

British American Tobacco

Diageo

Legal & General Group PLC

LyondellBasell Industries

Reckitt Benckiser Group PLC

Unilever

For weeks, I have pounded the table about the historic opportunity in REITs. The fundamentals were clear that now was the best time in 14 years to buy REITs. Last week, stocks ripped 6% higher, and REITs soared 9%, powered by falling rates that were the only reason REITs had fallen. Today, there is another Warren Buffett-style "fat pitch" opportunity staring at you in plain sight. UK Stocks are trading at 10X earnings and 7X cash-adjusted earnings, a 30% historical discount.

9 Once-In-A Lifetime Blue-Chip Opportunities Yielding As Much As 10%

Smith & Nephew plc (NYSE:SNN ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 AM ET Company Participants Deepak Nath - Chief Executive Officer Anne-Francoise Nesmes - Chief Financial Officer Conference Call Participants Robert Davies - Morgan Stanley Veronika Dubajova - Citi Lisa Clive - Bernstein Jack Reynolds-Clark - RBC David Adlington - JPMorgan Graham Doyle - UBS Hassan Al-Wakeel - Barclays Sezgi Oezner - HSBC Operator Deepak Nath Good morning and welcome to the Smith & Nephew Third Quarter Trading Report Call. As mentioned, I'm Deepak Nath and is Chief Executive Officer and joining me is Chief Financial Officer, Anne-Francoise Nesmes.

Smith & Nephew plc (SNN) Q3 2023 Earnings Call Transcript

JPMorgan has upgraded the firm to overweight from neutral pointing out shares have de-rated to 10-year lows in recent weeks. This reflected concerns on a margin guidance downgrade post-H1 soft margins and secondly GLP-1 impact on procedures.

Smith & Nephew downgrade cycle coming to an end

Shares in Smith & Nephew PLC (LSE:SN) surged by 4.2% as the company projected sales growth to hit the upper end of its guidance following a robust third quarter, despite a slight tempering of margin growth expectations. The medical equipment manufacturer reported a 7.7% increase in third-quarter revenues, amounting to $1.36 billion.

Smith & Nephew shares up 4.2% on FY sales upgrade

LONDON , Oct. 11, 2023 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company specialising in orthopaedics, advanced wound management and sports medicine, is pleased to announce the opening of the purpose-built Smith+Nephew Academy Munich, a new centre for surgical innovation and training. S+N Academy Munich, situated in Kustermann Park in the heart of the city, will provide a central European hub for surgeons from across Europe, the Middle East and Africa.

Smith+Nephew opens new state-of-the-art surgical innovation and training centre in the heart of Munich

Abbott Labs

Royal Philips

Here we pick three stocks, Abbott Laboratories (ABT), Koninklijke Philips (PHG) and Smith & Nephew SNATS (SNN) from the Medical - Products industry, with a solid five-year dividend growth history.

3 Medical Product Stocks With Solid Dividend Yield: ABT & Others

Smith & Nephew (SNN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Smith & Nephew (SNN) Loses -5.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Smith & Nephew plc (NYSE:SNN ) Q2 2023 Earnings Conference Call August 3, 2023 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer Anne-Francoise Nesmes - Chief Financial Officer Conference Call Participants Jack Reynolds-Clark - RBC Hassan Al-Wakeel - Barclays Graham Doyle - UBS Veronika Dubajova - Citi David Adlington - JPMorgan Robert Davies - Morgan Stanley Chris Gretler - Credit Suisse Deepak Nath Good morning. Welcome to the Smith & Nephew Second Quarter and First Half Results Call.

Smith & Nephew plc (SNN) Q2 2023 Earnings Call Transcript

Smith & Nephew PLC (LSE:SN) reported improved revenue, profit and margin in the first half making progress towards achieving sustainable higher growth under its 12-point plan. In the six months to July 1, the medical equipment manufacturing company said revenue rose 5.2% to US$2.73 billion from US$2.60 billion the year before while operating profit climbed to US$275 million from US$242 million.

Smith & Nephew raises guidance after strong first half

Smith & Nephew plc is a long-standing company in the medical device sector, focusing on developing and manufacturing internationally. The company has recently received FDA clearance for its AETOS Shoulder System, aiming to gain market share in the shoulder replacement market. SNN's strong margins and presence in multiple markets provide potential for sustainable growth, but improvements in cash flows and margins are needed.

Smith & Nephew: Entering New Markets But Growth Is Slow Still

Boston Scientific

Centene

Elevance Health Inc

HCA Healthcare

Humana

Intuitive Surgical

Surgery Partners

Tenet Healthcare

UnitedHealth Group

Zimmer Biomet Hlds

After a pandemic pause, hip and knee replacements are back. Long-postponed surgeries are being rescheduled, which is bad for business at insurance companies like UnitedHealth Group Inc. NYSE: UNH, but potentially good business for surgery centers like Surgery Partners Inc. NASDAQ: SGRY and companies like Zimmer Biomet Holdings Inc. NYSE: ZBH that manufacture joint-replacement technologies.

Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand

LONDON , June 12, 2023 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its AETOS Shoulder System. Designed to restore patients' range-of-motion1-4 and help minimize arthritic shoulder pain.

Smith+Nephew announces 510(k) clearance of its AETOS™ Shoulder System for anatomic and reverse shoulder replacement

LONDON , May 16, 2023 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today introduces two key products that close the feedback loop for its robotics and digital surgery portfolio – Personalized Planning powered by AI and RI.INSIGHTS Data Visualization Platform. These solutions transform data into contextual intelligence by enabling surgeons to see how pre-operative surgical plans and intra-operative decision-making link to post-operative outcomes.

Smith+Nephew helps personalize robotically-enabled surgery with AI-powered planning software and data visualization platform

Contract awarded for products that bring improvement to healthcare industry LONDON , May 2, 2023 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces its PICO Single Use Negative Pressure Wound Therapy Systems have received an Innovative Technology contract from Vizient, Inc. the nation's largest member-driven health care performance improvement company. The contract was awarded based on the recommendation of the PICO Single Use Negative Pressure Wound Therapy Systems by hospital experts who serve on one of Vizient's member-led councils, and it signifies to Vizient members unique qualities that potentially bring improvement to the healthcare industry.

Smith+Nephew receives Innovative Technology contract from Vizient for PICO™ Single Use Negative Pressure Wound Therapy Systems

Smith & Nephew PLC (LSE:SN) held full-year guidance as it reported strong growth in its Sports Medicine and Advanced Wound Management businesses had underpinned an improvement in first quarter revenue. The Watford-based medical equipment manufacturing company said revenue in the quarter to March 31 rose 3.8% on a reported basis to US$1.36 billion from US$1.31 billion or 6.9% on an underlying basis.

Smith & Nephew holds guidance as revenue rises 3.8%

LONDON , April 24, 2023 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today introduced its new CORI™ Digital Tensioner - a purpose built device that lets surgeons measure the ligament tension in a knee prior to cutting bone.1 By enabling a surgeon to quantify joint laxity in the native knee and achieve an optimal ligament tensioning force, the CORI Digital Tensioner helps to reduce variability when balancing the knee in surgery.1-4 This helps make surgical planning more objective versus other commercially available alternatives.1,3 Personalizing Surgery and Helping Reduce Variability in Robotics-assisted TKA The CORI Digital Tensioner produces a surgeon-defined, quantifiable force to distract the knee joint, apply consistent tension to the ligaments, and provide objective gap data for procedure planning and execution.1,3 A small clinical case series showed the CORI Digital Tensioner reduced variability of tensioning by 64% when compared to a manual technique.5* "I've never seen anything like the digital tensioner before," stated Dr. Steven Haas at Hospital for Special Surgery in New York. "You try to teach how much force to apply, but it varies by surgeon and from one case to another.

Smith+Nephew introduces first of its kind handheld digital tensioning device for robotically-enabled total knee arthroplasty

RBC Capital said expects Smith & Nephew PLC (LSE:SN) to post revenue growth of 3.9% in the first quarter, as the company benefits from positive trends in US elective procedures while facing headwinds in China. In a note to clients, the Canadian bank maintained an "outperform" rating and a £16 price target for the London-listed med-tech giant.

Smith & Nephew shares worth 'buying' up £16, says leading bank

Sanofi

You don't see financial TV channels dedicated to minute-by-minute coverage of dividend yield or increases, but for investors in companies like Sanofi (NASDAQ: SNY), AstraZeneca plc (NASDAQ: AZN), and Smith & Nephew plc (NYSE: SNN), there should be at least a little excitement about intrinsically boosting your stock's return every quarter.

3 Healthcare Dividend Payers With Big Price Growth

Smith & Nephew (SNN) achieves a positive response for its COBLATION-Technology-infused Intracapsular Tonsillectomy Technique, providing fast patient recovery over existing surgeries.

Smith & Nephew's (SNN) CIT Technology Favored by New Study

LONDON , March 23, 2023 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces results from new scientific research that shows its COBLATION Intracapsular Tonsillectomy (CIT) technique can lead to improved post-operative outcomes in patients versus total tonsillectomy techniques. The research was recently published online by OTO Open: The Open Access Journal of the American Academy of Otolaryngology-Head and Neck Surgery Foundation.

New evidence demonstrates Smith+Nephew's COBLATION™ Technology can accelerate patient recovery with fewer complications compared with total tonsillectomy techniques

Smith & Nephew PLC (LSE:SN) is in line to benefit from surgical trends flagged by a leading orthopaedic surgeon, analysts at Citi said. The bank hosted a call with Dr Samir Mehta, associate professor of orthopaedic surgery and chief of the Orthopedic Trauma and Fracture Care division at the Hospital of the University of Pennsylvania.

News for Smith & Nephew Stock (SNN)